138 related articles for article (PubMed ID: 34130465)
1. Changes in the co-expressions of interleukin 29 (IL-29), IFN-inducible protein 10 (IP-10) and monokine induced by IFNγ (MIG) genes in chronic hepatitis C Egyptian patients untreated and treated with DAAs.
Gaballah A; Naga IS; Zaghloul MS; Mostafa HM; Noby A
Acta Virol; 2021; 65(2):141-148. PubMed ID: 34130465
[TBL] [Abstract][Full Text] [Related]
2. IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection.
Wang Y; Hu Y; Zhang X; Luo Y; Ma L; Lu J; Liang Q; Xu C; Zhao C; Pan CQ
Front Public Health; 2022; 10():911551. PubMed ID: 35923969
[TBL] [Abstract][Full Text] [Related]
3. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
Fattovich G; Covolo L; Bibert S; Askarieh G; Lagging M; Clément S; Malerba G; Pasino M; Guido M; Puoti M; Gaeta GB; Santantonio T; Raimondo G; Bruno R; Bochud PY; Donato F; Negro F;
Aliment Pharmacol Ther; 2011 May; 33(10):1162-72. PubMed ID: 21443535
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients.
Derbala M; Rizk NM; Al-Kaabi S; John A; Sharma M; El-dweik N; Yakoob R; Pasic F; Almohanadi M; Alejji K; Abdelmola A; Butt M
Virology; 2013 Sep; 444(1-2):292-300. PubMed ID: 23866096
[TBL] [Abstract][Full Text] [Related]
5. Serum inducible protein-10 chemokine as a biomarker for clearance of HCV with and without treatment in Egyptian patients.
Tabll A; El Shenawy R; Elsharkawy H; Mohamed FZ
Hum Antibodies; 2019; 27(4):265-273. PubMed ID: 31127759
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Interferon-γ (IFN-γ) and IFN-γ-Inducible Protein 10 (IP-10) Genes' Polymorphism on Risk of Hepatitis C Virus-Related Liver Cirrhosis.
Talaat RM; Elsharnoby S; Abdelkhalek MS; El-Shenawy SZ; Elmasry S
Immunol Invest; 2022 Apr; 51(3):688-704. PubMed ID: 33445993
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
8. Changes in serum interferon-γ-inducible protein-10 levels and liver stiffness among chronic hepatitis C Egyptian patients in response to directly acting antiviral agents.
El-Nahaas SM; Rady NH; Malek S; Serag K
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e335-e340. PubMed ID: 33470694
[TBL] [Abstract][Full Text] [Related]
9. CXCL9 chemokine level is associated with spontaneous clearance and sustained virological response in Egyptian Chronic Hepatitis C patients receiving direct acting antivirals.
Tabll AA; Afifi MS; El-Etrawy AS; El-Kousy SM; Smolic M; El Abd YS
Hum Antibodies; 2020; 28(2):141-148. PubMed ID: 32675406
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents.
Yousif MM; Elsadek Fakhr A; Morad EA; Kelani H; Hamed EF; Elsadek HM; Zahran MH; Fahmy Afify A; Ismail WA; Elagrody AI; Ibrahim NF; Amer FA; Zaki AM; Sadek AMEM; Shendi AM; Emad G; Farrag HA
Infez Med; 2018 Sep; 26(3):237-243. PubMed ID: 30246766
[TBL] [Abstract][Full Text] [Related]
11. Detection of hepatitis C virus (HCV) RNA in the peripheral blood mononuclear cells of HCV-infected patients following sustained virologic response.
Khattab MA; Zakaria Y; Sadek E; Abd El Fatah AS; Fouad M; Khattab M; Moness HM; Adel NM; Ahmed E
Clin Exp Med; 2023 Feb; 23(1):131-140. PubMed ID: 35066710
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-22 and Chemokine Interferon γ -Inducible-10 (IP-10) Levels in Chronic Hepatitis C Patients and Treatment Response to Pegylated Interferon and Ribavirin Therapy.
F GM; Attia FM; Saleh RM; M H; Anani M
Egypt J Immunol; 2017 Jun; 24(2):83-91. PubMed ID: 29528582
[TBL] [Abstract][Full Text] [Related]
13. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
Romero AI; Lagging M; Westin J; Dhillon AP; Dustin LB; Pawlotsky JM; Neumann AU; Ferrari C; Missale G; Haagmans BL; Schalm SW; Zeuzem S; Negro F; Verheij-Hart E; Hellstrand K;
J Infect Dis; 2006 Oct; 194(7):895-903. PubMed ID: 16960776
[TBL] [Abstract][Full Text] [Related]
14. Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
Meissner EG; Decalf J; Casrouge A; Masur H; Kottilil S; Albert ML; Duffy D
PLoS One; 2015; 10(7):e0133236. PubMed ID: 26181438
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-28B polymorphisms and interferon gamma inducible protein-10 serum levels in seronegative occult hepatitis C virus infection.
Bartolomé J; Castillo I; Quiroga JA; Carreño V
J Med Virol; 2016 Feb; 88(2):268-74. PubMed ID: 26147900
[TBL] [Abstract][Full Text] [Related]
16. Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4.
Al-Ashgar HI; Khan MQ; Helmy A; Al-Thawadi S; Al-Ahdal MN; Khalaf N; Al-Qahtani A; Sanai FM
Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):404-10. PubMed ID: 23470264
[TBL] [Abstract][Full Text] [Related]
17. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
Reiberger T; Aberle JH; Kundi M; Kohrgruber N; Rieger A; Gangl A; Holzmann H; Peck-Radosavljevic M
Antivir Ther; 2008; 13(8):969-76. PubMed ID: 19195322
[TBL] [Abstract][Full Text] [Related]
18. Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
Inglot M; Pawlowski T; Szymczak A; Malyszczak K; Zalewska M; Radkowski M
Postepy Hig Med Dosw (Online); 2013 Mar; 67():186-91. PubMed ID: 23619217
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.
Arnaud C; Pradat P; Spaziante M; Berthillon P; Maynard M; Taliani G; Chemin I; Trépo C; Petit MA
Antivir Ther; 2013; 18(8):1027-32. PubMed ID: 23948510
[TBL] [Abstract][Full Text] [Related]
20. Occult hepatitis C infection identified in injection drug users with direct antiviral agents therapy and spontaneous resolution of hepatitis C virus infection.
Silva E; Marques S; Leal B; Canhão B; Madaleno J; Simão A; Carvalho A
Virus Res; 2023 May; 329():199104. PubMed ID: 37003528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
